The European Commission (EC) signed a contract with Janssen Pharmaceutica NV (a Johnson & Johnson company) to purchase future potential COVID-19 vaccines. Should the vaccine prove effective, the deal includes 200 million doses of Janssen Pharmaceutica NV’s vaccine candidate, as well as the option to purchase 200 million more.
It also includes the potential to donate doses to lower- and middle-income countries or to redirect to other European countries. Janssen Pharmaceutica NV’s vaccine candidate is currently in large-scale phase III clinical trials.
This is the third contract that the EC has signed with a pharmaceutical company; the previous ones were with Sanofi-GSK and AstraZeneca.
Press release - European Commission